期刊
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
卷 42, 期 11, 页码 2000-2016出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/0271678X221116192
关键词
Biomarkers; cerebral ischemia; epigenomics; hemorrhagic stroke; neuroprotection
资金
- National Institutes of Health [R01NS099531, R01NS101960, R01NS109459]
- Department of Neurological Surgery, University of Wisconsin
- US Department of Veterans Affairs [IK6BX005690]
Epigenetic modifications play a central role in the progression of stroke pathology, regulating gene expression, cellular injury response, and functional outcomes after stroke. Technological advances in epigenetics may provide innovative targets and promising therapeutic approaches for stroke treatment.
Accumulating evidence indicates a central role for epigenetic modifications in the progression of stroke pathology. These epigenetic mechanisms are involved in complex and dynamic processes that modulate post-stroke gene expression, cellular injury response, motor function, and cognitive ability. Despite decades of research, stroke continues to be classified as a leading cause of death and disability worldwide with limited clinical interventions. Thus, technological advances in the field of epigenetics may provide innovative targets to develop new stroke therapies. This review presents the evidence on the impact of epigenomic readers, writers, and erasers in both ischemic and hemorrhagic stroke pathophysiology. We specifically explore the role of DNA methylation, DNA hydroxymethylation, histone modifications, and epigenomic regulation by long non-coding RNAs in modulating gene expression and functional outcome after stroke. Furthermore, we highlight promising pharmacological approaches and biomarkers in relation to epigenetics for translational therapeutic applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据